Want to see AU:LGP full AI Analyst Report?
LGP Stock Chart & Stats
AU$0.10
<AU$0.01(1.67%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(1.67%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.14
Previous CloseN/A
Volume21.69K
Average Volume (3M)172.00K
Market Cap
AU$53.82M
Enterprise ValueAU$28.30T
Total Cash (Recent Filing)AU$1.42M
Total Debt (Recent Filing)AU$4.69M
Price to Earnings (P/E)―
Beta0.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding827,978,700
10 Day Avg. Volume171,934
30 Day Avg. Volume172,001
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage gives LGP greater financial flexibility than a heavily indebted business, helping it withstand operating volatility and preserve capacity for product development, market expansion, or other investment. Debt reduction versus earlier years further supports balance-sheet resilience.
Long-term Revenue ScaleThe substantial increase in revenue over several years indicates that LGP has built a materially larger commercial business and expanded product sales beyond its early base. This scale can support broader market reach and improve operating leverage if demand and margins stabilize.
Improving Cash BurnThe move toward breakeven operating cash flow represents meaningful progress from earlier periods of substantial cash outflow. If maintained, better cash conversion could reduce dependence on external funding and provide a more durable foundation for ongoing medicinal-cannabis operations.
Bears Say
Recent Revenue ContractionThe latest revenue decline interrupts LGP’s longer-term scaling trajectory and indicates that recent demand, product mix, or market execution has not been consistently sustained. Continued contraction would reduce operating leverage and make it harder to absorb fixed business costs.
Inconsistent ProfitabilityUnstable earnings and recurring negative operating profit show that revenue scale has not yet translated into dependable core profitability. This weakens internal funding capacity, makes performance more sensitive to non-operating items, and limits confidence in sustainable earnings generation.
Negative Free Cash FlowLGP is still not consistently funding its investment and operating needs through internally generated cash. Persistent negative free cash flow can require external capital over time, constrain strategic flexibility, and leave the company more exposed if cash conversion does not continue improving.
Little Green Pharma Ltd. News
LGP FAQ
What was Little Green Pharma Ltd.’s price range in the past 12 months?
Little Green Pharma Ltd. lowest share price was AU$0.06 and its highest was AU$0.14 in the past 12 months.
What is Little Green Pharma Ltd.’s market cap?
Little Green Pharma Ltd.’s market cap is AU$53.82M.
When is Little Green Pharma Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Little Green Pharma Ltd.’s earnings last quarter?
Currently, no data Available
Is Little Green Pharma Ltd. overvalued?
According to Wall Street analysts Little Green Pharma Ltd.’s price is currently Overvalued.
Does Little Green Pharma Ltd. pay dividends?
Little Green Pharma Ltd. does not currently pay dividends.
What is Little Green Pharma Ltd.’s EPS estimate?
Little Green Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Little Green Pharma Ltd. have?
Little Green Pharma Ltd. has 827,978,700 shares outstanding.
What happened to Little Green Pharma Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Little Green Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:LGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Little Green Pharma Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.57%
12-Months-Change
Fundamentals
Return on Equity
-1.67%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Little Green Pharma Ltd.
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―